Results 51 to 60 of about 191 (118)

Clinical efficiency of medium and high doses of valsartan in the treatment of patient with arterial hypertension and chronic kidney diseases

open access: yesRUDN Journal of Medicine, 2010
The results of the study, which shows the efficiency of antihypertensive and nephroprotektive angiotensin II receptor blocker valsartan in patients with arterial hypertension of and chronic kidney disease.
M L Maximov, O V Dralova
doaj  

Клиническое применение цистатина С как предиктора острого почечного повреждения после радикального хирургического лечения пациентов с мышечно-инвазивным раком мочевого пузыря

open access: yesИсследования и практика в медицине, 2021
Цель исследования. Оценить клинико-прогностическую значимость сывороточного и мочевого цистатина С (uCys-C и sCys-C) у пациентов, перенесших радикальную цистэктомию (РЦЭ), в отношении возникновения ОПП.Пациенты и методы. В этом проспективном исследовании

doaj  

[The short test with hydrochlorothiazide in differential diagnosis between primary normocalcemic and secondary hyperparathyroidism for inpatient treatment]. [PDF]

open access: yesProbl Endokrinol (Mosk), 2022
Eremkina AK   +9 more
europepmc   +1 more source

Immunological aspects of the development of hypertension and renal dysfunction in patients with chronic diseases of joints

open access: yesRUDN Journal of Medicine, 2012
The article is devoted to the study of the role of inflammation in the vascular lesions and visceral development in rheumatoid arthritis as autoimmunnom disease with a pronounced inflammatory component.
A V Safronenko   +4 more
doaj  

[FGF23 tumor induced osteomalacia]. [PDF]

open access: yesProbl Endokrinol (Mosk), 2022
Gronskaia SA, Belaya ZE, Melnichenko GA.
europepmc   +1 more source

Витамин D и хроническая болезнь почек

open access: hybrid, 2012
S.V. Kushnirenko   +2 more
openalex   +2 more sources

[The impact of carbohydrate metabolism disorders on the early and long-term clinical outcomes of patients with COVID-19 according to the AKTIV and AKTIV 2 registries]. [PDF]

open access: yesProbl Endokrinol (Mosk), 2023
Salukhov VV   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy